8results about How to "Minimize side effects" patented technology

The invention relates to the technical field of intelligent medicine management, in particular to a medicine management method and system for old people. Based on the medication data of the old people, the absorption, distribution, metabolism and excretion processes of the medicine in the body are simulated, data analysis is carried out, and medicine dynamic analysis auxiliary information is generated. According to the method, numerical simulation is carried out on the absorption rate of the medicine in the body, so that medicine management can accurately calculate the behavior and effect of the medicine in the body according to the individual difference of old people, and medicine dosage adjustment is provided for old patients, especially for the situation that the dosage needs to be accurately controlled, such as management of anticoagulant medicine. Through accurate simulation, the health risk caused by improper dosage of the medicine can be reduced to the greatest extent. Secondly, by constructing a state and reward matrix, data-driven decision support is provided for selection and dose adjustment of each medicine;

A ferritin fusion protein according to an embodiment includes a cancer-targeting peptide and a peptide to be cleaved in a cancer cell linked to an outer surface thereof. The ferritin fusion protein may enable efficient cancer-targeting treatment by releasing an anticancer drug specifically in a cancer cell, has excellent anticancer efficacy, and can effectively reduce toxicity to a normal cell, thereby minimizing side effects of anticancer treatment.

The present invention relates to a drug delivery system for application to the esophageal mucosa, comprising at least one sheet-like formulation, in particular a film-shaped, foil-shaped or sheet-shaped formulation, comprising a reflux inhibitor, a release mechanism, and a trigger mechanism, the trigger mechanism being adapted to trigger the release of the sheet-like formulation by the release mechanism at a predetermined site of action.

This invention provides a lithium secondary battery, comprising: a battery casing; an electrode assembly housed within the battery casing; and an electrolyte, wherein the electrode assembly includes a positive electrode comprising a positive electrode active material, a separator, and a negative electrode comprising a negative electrode active material, and the electrolyte comprises LiPF6 as a lithium salt and ethylene carbonate as an organic solvent, wherein the ratio of the diameter (r) to the height (h) of the battery casing of the lithium secondary battery (shape factor ratio) is 0.4 or more, and satisfies the condition of mathematical formula (1), wherein in mathematical formula (1), h is the height (mm) of the battery casing, r is the diameter (mm) of the battery casing, and W LiPF6 The amount of LiPF6 relative to the total weight of the electrolyte, expressed as a percentage (%), W EC It is the amount of ethylene carbonate relative to the total weight of the electrolyte, expressed as a percentage (%), and W EL This represents the total weight (g) of the electrolyte contained in the lithium secondary battery. [Mathematical formula (1)]

The present invention relates to an oncolytic virus and the use thereof, and specifically, an oncolytic virus having suppressed expression of a thymidine kinase (TK) gene and comprising genes encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a complement regulatory protein; and the use of such a oncolytic virus . The oncolytic virus of the present invention maintains its efficacy even upon intravenous injection, and thus, it may also be applied to the treatment of various solid carcinomas and metastatic cancers in addition to superficial solid cancers. In addition, the oncolytic virus of the present invention acquires resistance to the attack of the body's complement system by expressing a complement regulatory protein on the surface of the virus, and thus, it is stable in the blood, and it maintains stable oncolytic activity upon intravenous injection, and thus, it may reduce the dose of the virus to minimize the side effects of anti-cancer drugs. Therefore, the oncolytic virus of the present invention may be usefully used for preventing or treating cancer.

This invention relates to the use of peptides as therapeutic agents for degenerative brain diseases. Specifically, it confirms that the peptides of this invention, by targeting microglia, induce microglia in an inflammatory state to an anti-inflammatory state in a disease environment, thereby reducing neuroinflammation and enhancing phagocytic function to clear amyloid-β. Furthermore, in animal models of degenerative brain diseases, the effects of reducing amyloid-β, restoring synaptic plasticity, and improving cognitive impairments related to anxiety, learning, and memory have been confirmed. Therefore, the peptides of this invention can be effectively used as active ingredients in compositions for the prevention or treatment of degenerative brain diseases and the resulting cognitive, learning, or memory impairments.

The present invention provides a dispersion composition comprising: a dispersion medium; and particles comprising a target substance. The dispersion composition comprises at least one surfactant at a concentration above the critical micelle concentration, and does not comprise a solubilizer. The target substance is cyclosporin A, and satisfies the previously defined S-parameter > 1.

The present invention relates to a drug delivery system for application to the esophageal mucosa, comprising at least one sheet-like formulation, in particular a film-shaped, foil-shaped or sheet-like formulation, comprising an anti-inflammatory agent or a salt thereof, a release mechanism, and a triggering mechanism, the triggering mechanism being adapted to trigger the release of the sheet-like formulation by the release mechanism at a predetermined site of action.